[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345877-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345877-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pancreatic-acinar-cell-carcinoma-a-rare-pancreatic-malignancy-with-distinct-biology-and-emerging-therapeutic-opportunities","Pancreatic Acinar Cell Carcinoma - A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities","","Pancreatic acinar cell carcinoma (PACC) is a rare exocrine pancreatic malignancy accounting for approximately 1–2% of adult pancreatic neoplasms. Accumulating evidence shows PACC is biologically distinct from pancreatic ductal adenocarcinoma (PDAC), with different clinical presentation, pathology, and molecular features. Compared with PDAC, PACC more often presents as a large mass, has lower obstructive jaundice rates, and shows lower KRAS mutation frequency. Genomic studies identify recurrent DNA repair and WNT/β-catenin alterations and actionable kinase fusions, including BRAF and RAF1 rearrangements.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pancreatic-acinar-cell-carcinoma-a-rare-pancreatic-malignancy-with-distinct-biology-and-emerging-therapeutic-opportunities/345877/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pancreatic-acinar-cell-carcinoma-a-rare-pancreatic-malignancy-with-distinct-biology-and-emerging-therapeutic-opportunities/345877.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How common is pancreatic acinar cell carcinoma (PACC) among adult pancreatic neoplasms?","Question",{"text":63,"@type":64},"PACC accounts for approximately 1–2% of adult pancreatic neoplasms, and reported incidence ranges from about 0.2% to 4.3% in adult series.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What distinguishes PACC from pancreatic ductal adenocarcinoma (PDAC)?",{"text":68,"@type":64},"PACC has distinct clinical, pathologic, and molecular characteristics, including a tendency toward larger pancreatic masses, less frequent obstructive jaundice, and lower KRAS mutation rates.",{"name":70,"@type":61,"acceptedAnswer":71},"What molecular alterations are commonly reported in PACC and how may they guide therapy?",{"text":72,"@type":64},"Recurrent alterations involve DNA damage repair pathways and WNT/β-catenin signaling, and actionable kinase fusions such as BRAF and RAF1 rearrangements, supporting precision oncology approaches.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345877,1790334273,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nPancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities  \nNoor Farhoud 1,*, Raed Moh’d Taiseer Al-Rajabi 2, Joaquina Celebre Baranda 2, Haoran Li 2, Wei Zhang 2, Ravi Kumar Paluri 3, Ashish Manne 4, Prasad Dandawate 5, Weijing Sun 2 and Anup Kasi 2, *  \nAcademic Editor: Makoto Abue  \nReceived: 16 June 2026  \nRevised: 8 July 2026  \nAccepted: 12 July 2026  \nPublished: 17 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA  \n2 Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA  \n3 Department of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA  \n4 Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA  \n5 Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA  \n* [Correspondence: nfarhoud@kumc.edu](Correspondence: nfarhoud@kumc.edu) (N.F.); [akasi@kumc.edu](akasi@kumc.edu) (A.K.)  \nSimple Summary  \nPancreatic acinar cell carcinoma is a rare exocrine pancreatic malignancy with clinical, pathologic, and molecular features that distinguish it from pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Due to its rarity, many aspects of its diagnosis and treatment remain poorly understood, and most available evidence comes from small studies. This review summarizes current knowledge about how pancreatic acinar cell carcinoma presents, its unique biological and genetic features, available treatment approaches, and factors that influence patient outcomes. Recent research has shown that this cancer often contains specific genetic alterations that may be targeted with personalized therapies, creating new opportunities for treatment. By bringing together the latest clinical and molecular evidence, this review aims to improve awareness of this rare disease, support more informed treatment decisions, and highlight areas where future research may lead to better outcomes for patients.  \nAbstract  \nPancreatic acinar cell carcinoma (PACC) is a rare exocrine pancreatic malignancy accounting for approximately 1–2% of adult pancreatic neoplasms. Although historically grouped with pancreatic ductal adenocarcinoma (PDAC), accumulating evidence demonstrates that PACC represents a biologically distinct entity with unique clinical, pathologic, and molecular characteristics. Compared with PDAC, PACC more commonly presents as a large pancreatic mass, is less frequently associated with obstructive jaundice, and exhibits lower rates of KRAS mutations. Recent genomic studies have identified recurrent alterations involving DNA damage repair pathways, WNT/β-catenin signaling, and actionable kinase fusions, including BRAF and RAF1 rearrangements. In advanced disease, fluoropyrimidineand platinum-based regimens appear to demonstrate greater activity than traditional gemcitabine-based approaches, although prospective comparative data are lacking. This review summarizes the current understanding of the epidemiology, clinical presentation, pathology, molecular landscape, treatment approaches, and prognostic factors associated with PACC. We highlight emerging opportunities for precision oncology and discuss ongoing challenges in the management of this uncommon pancreatic malignancy.  \nKeywords: pancreatic acinar cell carcinoma; pancreatic cancer; acinar cell carcinoma; molecular profiling; gene fusions; BRAF fusion; homologous recombination deficiency; targeted therapy; immunotherapy; precision oncology; pancreatic neoplasms  \n1. Introduction  \nPancreatic acinar cell carcinoma (PACC) is a rare exocrine mali","cbCaipyHvmEF71ZK","https://ap.wps.com/l/cbCaipyHvmEF71ZK","pdf",3126746,15,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction\n## Epidemiology\n## Clinical presentation and management\n## Molecular characteristics and distinct biology","[{\"question\":\"How common is pancreatic acinar cell carcinoma (PACC) among adult pancreatic neoplasms?\",\"answer\":\"PACC accounts for approximately 1–2% of adult pancreatic neoplasms, and reported incidence ranges from about 0.2% to 4.3% in adult series.\"},{\"question\":\"What distinguishes PACC from pancreatic ductal adenocarcinoma (PDAC)?\",\"answer\":\"PACC has distinct clinical, pathologic, and molecular characteristics, including a tendency toward larger pancreatic masses, less frequent obstructive jaundice, and lower KRAS mutation rates.\"},{\"question\":\"What molecular alterations are commonly reported in PACC and how may they guide therapy?\",\"answer\":\"Recurrent alterations involve DNA damage repair pathways and WNT/β-catenin signaling, and actionable kinase fusions such as BRAF and RAF1 rearrangements, supporting precision oncology approaches.\"}]","Pancreatic Acinar Cell Carcinoma - A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities | PDF",1790059210,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/367840d45480e2e705a9b204299bcb75.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f151c6d0a4380a5ce88da11a9b844f3d.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90fee3a227f6b3d200dfc9cb489ed4f1.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75c8616c7c8d4fea0f50397d4c5e0d0a.webp",980,1385]